SarcopeniaNCT05688150
Prevalence and Associated Factors of Sarcopenia Among Elderly Patients in Osteoporosis Clinic
An observational study of Sarcopenia and Osteoporosis, run by Kowloon Hospital, Hong Kong at 1 site in Hong Kong.
Trial summary
This was a cross-sectional study. Patients who attended the osteoporosis clinic of Kowloon Hospital from June to December 2022 were recruited. Grip strength and appendicular skeletal muscle mass index were measured with a Jamar dynamometer and a bioimpedance analyser. Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Sarcopenia, Osteoporosis
- How many people
- 94 participants
- Where
- 1 siteHong Kong
- Study dates
- 20 Jun 2022to 28 Feb 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who attended the osteoporosis clinic of Kowloon Hospital from June to December 2022.
Who may be able to join
- Patients aged 60 years old or above
- Diagnosed with osteoporosis by: Fragility fracture or T-score ≤-2.5 SDs at any site on DXA scan and;
- Able to read and write Chinese
Who cannot join
- Unable to maintain standing posture for bioimpedance analysis
- Modified Functional Ambulation Classification (MFAC) ≤ IV
- Incompetent in giving consent
- Unable to follow instructions
- Implanted with metal in any of four limbs
- Implanted with pacemaker, implantable cardioverter defibrillator or any other types of electrical device
Trial locations and contacts
1 site in 1 country.
About this study
This was a cross-sectional study. Patients who attended the osteoporosis clinic of Kowloon Hospital from June to December 2022 were recruited.
Grip strength and appendicular skeletal muscle mass index were measured with a Jamar dynamometer and a bioimpedance analyser. Since most patients in our clinic are of Chinese ethnicity, the diagnostic criteria in the Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia in 2019 was utilised. The diagnosis of sarcopenia was established by the presence of both low grip strength (Male: < 28 kg, Female < 18 kg) and low appendicular skeletal mass (Male: < 7.0 kg/m2, Female: < 5.7 kg/m2)
- Conditions
- Sarcopenia, Osteoporosis
- Keywords
- osteosarcopenia, sarcopenia, osteoporosis, geriatric medicine
- Medical subject headings
- Sarcopenia, Osteoporosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Sarcopenia
The diagnosis of sarcopenia would be established by the co-existence of low grip strength and low appendicular skeletal muscle mass.
Measured: June - December 2022
Grip strength
Grip strength would be measured with Jamar digital dynamometer.
Measured: June - December 2022
Appendicular Skeletal Muscle Mass Index
Appendicular Skeletal Muscle Mass Index would be measured with bioimpedance analyzer.
Measured: June - December 2022
Secondary outcomes (4)
Association between BMI and Sarcopenia.
BMI would be measured on clinic attendance.
Measured: June - December 2022
Association between Frailty and Sarcopenia.
Clinical Frailty Scale would be documented in clinical consultation.
Measured: June - December 2022
Association between Charlson Comorbidities Index and Sarcopenia
Components of Charlson Comorbidities Index would be extracted from medical record.
Measured: June - December 2022
Association between Bone Mineral Densities and Sarcopenia
Bone mineral densities of spine and neck of femur would be extracted from the report of dual-energy X-ray absorptiometry.
Measured: June - December 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2023
- Study start20 Jun 2022
- Primary completion12 Dec 2022
- Study completion28 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 94 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kowloon Hospital, Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Leung Hin Cheung, Kowloon Hospital, Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05688150
- Sponsor's protocol ID
- KHRehab_LeungHC_1
- Status last verified
- Feb 2024
- First submitted
- 21 Dec 2022
- Last updated
- 20 Feb 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4.
PubMed 32033882
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence and Associated Factors of Sarcopenia Among Elderly Patients in Osteoporosis Clinic
- ClinicalTrials.gov ID
- NCT05688150
- Acronym / sponsor ID
- KHRehab_LeungHC_1
- Conditions
- Sarcopenia, Osteoporosis
- Keywords
- osteosarcopenia, sarcopenia, osteoporosis, geriatric medicine
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 94 participants (actual)
- Lead sponsor
- Kowloon Hospital, Hong KongUniversity, hospital or other
- Study start
- 20 Jun 2022 (actual)
- Primary completion
- 12 Dec 2022 (actual)
- Study completion
- 28 Feb 2023 (actual)
- First posted
- 18 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This was a cross-sectional study. Patients who attended the osteoporosis clinic of Kowloon Hospital from June to December 2022 were recruited.
Grip strength and appendicular skeletal muscle mass index were measured with a Jamar dynamometer and a bioimpedance analyser. Since most patients in our clinic are of Chinese ethnicity, the diagnostic criteria in the Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia in 2019 was utilised. The diagnosis of sarcopenia was established by the presence of both low grip strength (Male: < 28 kg, Female < 18 kg) and low appendicular skeletal mass (Male: < 7.0 kg/m2, Female: < 5.7 kg/m2)
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who attended the osteoporosis clinic of Kowloon Hospital from June to December 2022.
Key inclusion criteria (3 listed)
- Patients aged 60 years old or above
- Diagnosed with osteoporosis by: Fragility fracture or T-score ≤-2.5 SDs at any site on DXA scan and;
- Able to read and write Chinese
Key exclusion criteria (6 listed)
- Unable to maintain standing posture for bioimpedance analysis
- Modified Functional Ambulation Classification (MFAC) ≤ IV
- Incompetent in giving consent
- Unable to follow instructions
- Implanted with metal in any of four limbs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of Sarcopenia
Time frame: June - December 2022
The diagnosis of sarcopenia would be established by the co-existence of low grip strength and low appendicular skeletal muscle mass.
Grip strength
Time frame: June - December 2022
Grip strength would be measured with Jamar digital dynamometer.
Appendicular Skeletal Muscle Mass Index
Time frame: June - December 2022
Appendicular Skeletal Muscle Mass Index would be measured with bioimpedance analyzer.
4 secondary outcomes
Association between BMI and Sarcopenia.
Time frame: June - December 2022
Association between Frailty and Sarcopenia.
Time frame: June - December 2022
Association between Charlson Comorbidities Index and Sarcopenia
Time frame: June - December 2022
Association between Bone Mineral Densities and Sarcopenia
Time frame: June - December 2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2024.
- Background: PubMed 32033882Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020 Feb 4.
- Individual participant dataSharing planned: No
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia and Osteoporosis, run by Kowloon Hospital, Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of Sarcopenia (time frame: June - December 2022). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05688150, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2024.